Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors

Urology

Volumn 81, Issue 5, 2013, Pages 979-985

  Shelton, Peter Q ^a   Ivanowicz, Allie N ^a   Wakeman, Carolyn M ^a   Rydberg, Michael G ^a   Norton, James ^a   Riggs, Stephen B ^a,b   Teigland, Chris M ^a,b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CRYOTHERAPY; DISEASE SURVEILLANCE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; GYNECOMASTIA; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATECTOMY; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VERY LOW RISK PROSTATE CANCER;

EID: 84876673116     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.10.089     Document Type: Article

References (17)

1. G.L. Andriole Overview of pivotal studies for prostate cancer risk reduction, past and present Urol 73 2009 36 43
2. R. Seigel, E. Ward, and O. Brawley Cancer statistics, 2011 CA Cancer J Clin 61 2011 212 236
3. National Comprehensive Cancer Network. NCCN Prostate Cancer Guidelines. 2011.
4. A. Thorpe, and D. Neal Benign prostatic hyperplasia Lancet 361 2003 1359 1367
5. G.L. Andriole, C. Roehrborn, and C. Schulman Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia J Urol 64 2004 537 543
6. Y.C. Cohen, K.S. Liu, and N.L. Heyden Due to the effect of finasteride on prostate volume: a modeling approach for analysis of the prostate cancer prevention trial J Natl Cancer Inst 99 2007 1366 1374
7. I.M. Thompson, D.P. Ankerst, and C. Chi Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial J Clin Oncol 25 2007 3076 3081
8. E.A. Klein, C.M. Tangen, and P.J. Goodman Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisited J Clin Oncol 23 2005 7460 7466
9. C.G. Roehrborn, J.C. Nickel, and G.L. Andriole Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the Reduction by Dutasteride of Prostate Cancer Events trial J Urol 78 2011 641 647
10. A. Finelli, G. Trottier, and N. Lawrentschuk Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer Eur Urol 59 2011 509 514
11. N.E. Fleshner, M.S. Lucia, and B. Egerdie Dutasteride in localized prostate cancer management: the REDEEM randomized, double-blind, placebo-controlled trial Lancet 379 2012 1103 1111
12. I.M. Thompson, C. Chi, and D.P. Ankerst Effect of dutasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133
13. G.S. Merrick, K.E. Wallner, and W.M. Butler Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland J Urol 169 2003 1643 1652
14. D.A. Levy, and J.S. Jones Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes Urology 77 2011 994 998
15. J.P. Meyer, C.R.W. Bell, and C. Elwell Brachytherapy for prostate cancer: is the pretreatment prostate volume important? BJU Int 102 2008 1586 1588
16. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
17. V.B. Shahinian Androgen deprivation for prostate cancer: the case for "first, do no harm." Cancer 118 2012 3232 3235